This Year's Highlights

• Most Promising New Business, Finalist 10/02, Winner 5/03 Innovator of the Year (3/03) Grace & Franklin Bernsen Foundation, Technology Business Finance Award (5/04) Million Dollar Hall of Fame (5/04) Overall Innovator of the Year(4/05)
• 2005: Reached acquisition of over 11,000 patient specimens in 5 geographies and genotyping for each of 117 carcinogenisis SNPs. 8,000 patient with and without breast cancer
• 2005: Completed laboratory build-out of 11,000 sq. ft. clincal laboratory, research laboratory and office space in 655 Research Parkway for CLIA commercial laboratory 2006: FDA IDE for patient utilization of OncoVue and physician impact assessment

Anticipated Highlights

• -Publish multiple papers in peer reviewed journals on data collected from our existing study of 11,000 patients for OncoVue -Complete $5MM capital raise of over allotment in existing round -Launch DVT/coagulation SNP test from our CLIA lab.
• --Launch P450 SNP test from our CLIA Laboratory -Secure international marketing and R&D partnerships with existing tests and ongoing research studies -Ability to generate $4.8MM from study by providing results to patients under IDE
• -Complete FDA IDE OncoVue study in 12,000 patients in 50 centers -File and receive FDA approval for marketing of first FDA approved genetic-based breast cancer risk test

Corporate Mission

To identify individuals who are genetically predisposed to
potentially fatal diseases and provide medical intervention
to change the future outcome of their genetic risk